34657-67-5

Basic information

• Product Name: 2,4-Imidazolidinedione, 5,5-diphenyl-3-(phenylmethyl)-
• CAS NO: 34657-67-5
• Molecular Formula: C22H18N2O2
• Molecular Weight: 342.397
• Mol File: 34657-67-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2,4-Imidazolidinedione, 5,5-diphenyl-3-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Imidazolidinedione, 5,5-diphenyl-3-(phenylmethyl)-(34657-67-5)
• EPA Substance Registry System: 2,4-Imidazolidinedione, 5,5-diphenyl-3-(phenylmethyl)-(34657-67-5)

Safety Data

• Hazardous Substances Data: 34657-67-5(Hazardous Substances Data)

Upstream product

• 103269-28-9 3-benzyl-2-benzylmercapto-5,5-diphenyl-3,5-dihydro-imidazol-4-one 
• 57-41-0 phenythoin 
• 100-44-7 benzyl chloride 
• 100-46-9 benzylamine 
• 3060-50-2 2,2-diphenylglycine 
• 538-32-9 benzylurea 
• 134-81-6 benzil 
• 21083-47-6 5,5-diphenyl-2-thioxoimidazolidin-4-one 
• 22544-70-3 2-(methylthio)-4,4-diphenyl-5-imidazolinone 
• 2032-16-8 4-methylsulfanyl-5,5-diphenyl-1,5-dihydro-imidazol-2-one 
• 3718-53-4 4-methylsulfanyl-5,5-diphenyl-1,5-dihydro-imidazole-2-thione 
• 2032-17-9 2,5-bis-methylsulfanyl-4,4-diphenyl-4H-imidazole 
• 100-39-0 benzyl bromide 
• 201230-82-2 carbon monoxide 

Downstream Products

• 55251-18-8 3-benzyl-1-methyl-5,5-diphenyl-imidazolidine-2,4-dione 

Relevant articles and documents

Oligomer-containing hydantoin compounds

The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oli

Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives

Series of 3-alkyl, 3-aryl-5,5-diphenylimidazolidine-2,4-diones (2-8) and 3-phenacyl-5,5-diphenylimidazolidine-2,4-diones (9-20) were designed, synthesized, and tested for their antitumor activity. The 13 compounds (3-8, 10-15 and 20) were selected by Nati

Solvent effects on the structure-property relationship of some potentially pharmacologically active 3-(4-substituted benzyl)-5-ethyl-5-phenyl- and 3-(4-substituted benzyl)-5,5-diphenylhydantoins

Two series of 3-(4-substituted benzyl)-5-ethyl-5-phenyl- and 3-(4-substituted benzyl)-5,5-diphenylhydantoins were synthesized and their UV absorption spectra were recorded in the region 200-400 nm in selected solvents of different polarity. The effects of solvent dipolarity/polarizability and solvent/solute hydrogen bonding interactions on the spectral shifts were analyzed by means of the linear solvation energy relationship (LSER) methodology of Kamlet and Taft. The quantitative relationships between hydrogen bonding interactions and the lipophilicity and blood-brain permeation of the studied compounds were discussed. Satisfactory linear dependences were obtained for moderate electron-donating and electron-withdrawing substituents at the benzyl moiety, while the strong electron-withdrawing substituent (NO2) significantly modifies the solvation characteristics of the molecule. The paper clearly demonstrates how the solvatochromic comparison method may be applied to estimate the contributions of various modes of solvation to the pharmaceutically relevant properties of these newly synthetized hydantoin derivatives.